EPO: Appeal Board vetoes EPC regulation

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

EPO: Appeal Board vetoes EPC regulation

Veto final

In the latest international briefing for the EPO, Jakob Pade Frederiksen looks at the law around the patenting of plant and animal varieties as well as biological processes for the production of plants and animals

Following the so-called Tomato II and Broccoli II decisions rendered by the EPO's Enlarged Board of Appeal (EBA) in 2015, the politically delicate question of patentability of plant or animal varieties as well as essentially biological processes for the production of plants or animals has once again occupied the EPO, now with the uncomfortable implication that a Technical Board of Appeal of the EPO has revealed a conflict between two legal provisions within the framework of the EPC.

The Tomato II and Broccoli II decisions, G 2/12 and G 2/13, held that products derived from essentially biological processes may be patentable, even if the process used to obtain the product is essentially biological and hence not patentable. In particular, the EBA concluded that Article 53(b) EPC, excluding plant or animal varieties and essentially biological processes for the production of plants or animals from patentability, did not extend to plants or plant material or plant parts other than a plant variety.

In the wake of these decisions, the European Commission released a notice in November 2016 stating that the EU legislator's intention when adopting the Biotech Directive (98/44/EC) was to exclude from patentability plants, animals and parts thereof obtained by means of essentially biological processes. Against this background, the Administrative Council of the EPO implemented as of July 1 2017 new Rule 28(2) EPC specifying that under Article 53(b) EPC, "European patents shall not be granted in respect of plants or animals exclusively obtained by means of an essentially biological process."

According to decision T 1063/18 concerning the refusal under Rule 28(2) EPC of EP 2 753 168, made available on February 5 2019, a Technical Board of Appeal of the EPO held that Rule 28(2) EPC is in conflict with Article 53(b) EPC, as interpreted by the EBA in the above-referred decisions. In accordance with Article 164(2) EPC, the Appeal Board held that the provisions of the convention, i.e. Article 53(b) EPC shall prevail. In other words, Rule 28(2) is null and void.

Given the public interest in the matter concerned and the ethical aspects involved, and having regard to political signals from relevant EU bodies, it seems likely that further legislative initiatives may soon be taken in order to resolve the conflict between EU legislators' views and the provisions of Article 53(b) EPC.

frederiksen.jpg

Jakob Pade Frederiksen

Inspicos P/S

Kogle Allé 2

DK-2970 Hoersholm

Copenhagen, Denmark

Tel: +45 7070 2422

Fax: +45 7070 2423

info@inspicos.com

www.inspicos.com

more from across site and SHARED ros bottom lb

More from across our site

The firm said adding capability in the French capital completes its coverage of all major patent litigation jurisdictions as it strives for UPC excellence
Marc Fenster explains how keeping the jury focused on the most relevant facts helped secure a $279m win for his client against Samsung
Clients are divided on what externally funded IP firms bring to the table, so those firms must prove why the benefits outweigh the downsides
Rahul Bhartiya, AI coordinator at the EUIPO, discusses the office’s strategy, collaboration with other IP offices, and getting rid of routine tasks
A boom in transactional work and a heightened awareness of IP have helped boost revenue for the rebranded commercial services team
Clemens Heusch, head of global litigation and dispute resolution at Nokia, tells us why open conversations – and respectful challenges – lead to the best results
Siegmund Gutman, who joined Mintz one year ago, explains the firm’s approach to life sciences litigation and what it means for hiring plans
The merger of two IP boutiques could prompt others to follow suit and challenge Australia’s externally funded firms
Law firm leaders say they are eager to make the most out of the market following a 'surprising' survey on in-house interest in IP monetisation
A defeat for AstraZeneca and Open Innovation Network's 20th anniversary were also among the top talking points this week
Gift this article